Home » Topics » Articles » Insight

Insight
RSS

Biotech Companies Turn To Practical Pharmacogenomics

March 22, 1999

Biotechnology Company Deals With Other Biotechnology Companies: Collaborations, Agreements, Equity Participation: January 1 - March 12, 1999

March 22, 1999

Vimrx's Incarnations Keep Pace With Changing Times

March 15, 1999

Biotech Mergers And Acquisitions: November 10, 1998 - March 1, 1999#

March 15, 1999

Venture Capital, PIPE, And Corporate Investments In Biotechnology Companies: February 1999

March 8, 1999

Other Financings Of Public Biotechnology Companies: February 1999

March 8, 1999

Alternate Financings Still Reign Supreme As Biotechs Scramble For Cash

March 8, 1999

Public Financing Of Biotechnology: February 1999

March 8, 1999

Money Raised By Biotech In 1999: January - February

March 8, 1999

New Arthritis Therapies Enter The Clinic And The Market

March 1, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.